Patent intelligence · US
US 10639278
Delivery of agents using metastable liposomes
Delivery of agents using metastable liposomes
Patent details — US 10639278
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 5, 2020
- Expiration
- Apr 30, 2040
- Applicant
- LIPELLA PHARMACEUTICALS, INC.
- Claims
- 29
- CPC classes
- A61K, A61K31/436, A61K49/0084, A61K9/0034
Quick answer
US 10639278 (Delivery of agents using metastable liposomes) is held by LIPELLA PHARMACEUTICALS, INC.. Status: granted. Granted May 5, 2020. Expires Apr 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- LIPELLA PHARMACEUTICALS, INC.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/436, A61K49/0084, A61K9/0034, A61K9/1272, A61P
More from LIPELLA PHARMACEUTICALS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 10639278?
US 10639278 (Delivery of agents using metastable liposomes) is held by LIPELLA PHARMACEUTICALS, INC.. Status: granted. Granted May 5, 2020. Expires Apr 30, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10639278?
LIPELLA PHARMACEUTICALS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 4 pharmaceutical patents for this assignee.
When does US 10639278 expire?
Our index shows an expiration date of Apr 30, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.